MARKET

HEPA

HEPA

Hepion Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.960
-0.210
-9.68%
After Hours: 1.920 -0.04 -2.04% 19:57 02/25 EST
OPEN
2.120
PREV CLOSE
2.170
HIGH
2.130
LOW
1.960
VOLUME
10.88M
TURNOVER
--
52 WEEK HIGH
4.830
52 WEEK LOW
1.000
MARKET CAP
149.40M
P/E (TTM)
-0.7064
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering
ACCESSWIRE · 02/18 21:30
Thinking about buying stock in Sundial Growers, AMC Entertainment, Northern Dynasty Minerals, Citius Pharmaceuticals, or Hepion Pharmaceuticals?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, AMC, NAK, CTXR, and HEPA.
PR Newswire - PRF · 02/18 15:55
43 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 02/16 17:46
SOS, WPG, CAN and BLUE among midday movers
Gainers: Luokung Technology (LKCO) +112%.Kubient (KBNT) +63%.SOS (SOS) +58%.Torchlight Energy Resources (TRCH) +54%.Protective Insurance (PTVCB) +53%.500.com (WBAI) +45%.ALJ Regional (ALJJ) +45%.Urban Tea (MYT) +44%.Canaan (CAN) +36%.Applied Genetic Techno...
Seekingalpha · 02/16 17:37
Diffusion Pharmaceuticals, Strongbridge Biopharma leads healthcare gainers; bluebird bio, Cortexyme among major losers
Gainers: Diffusion Pharmaceuticals (DFFN) +36%, Strongbridge Biopharma (SBBP) +25%, KemPharm (KMPH) +20%, Senseonics Holdings (SENS) +17%, ReWalk Robotics (RWLK) +14%.Losers: bluebird bio (BLUE) -32%, Cortexyme (CRTX) -30%, Inhibrx (INBX) -28%, Hepion Phar...
Seekingalpha · 02/16 15:58
Mid-Morning Market Update: Gold Down 1.6%; Socket Mobile Shares Surge Higher
Following the market opening Tuesday, the Dow traded up 0.09% to 31,458.40, while the NASDAQ rose 0.50% to 14,095.47. The S&P also rose, gaining 0.47% to 3,934.83.
Benzinga · 02/16 15:55
Thinking about buying stock in Sundial Growers, Aslan Pharmaceuticals, Hepion Pharmaceuticals, Northern Dynasty Minerals, or Pyxis Tankers?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, ASLN, HEPA, NAK, and PXS.
PR Newswire - PRF · 02/16 15:48
DJ Hepion Pharmaceuticals Shares Drop After Stock Sale Prices
Dow Jones · 02/16 15:07
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HEPA. Analyze the recent business situations of Hepion Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HEPA stock price target is 10.00 with a high estimate of 12.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 5.47M
% Owned: 7.18%
Shares Outstanding: 76.23M
TypeInstitutionsShares
Increased
7
1.43M
New
27
3.81M
Decreased
3
43.41K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.53%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Director
Gary Jacob
Chief Executive Officer/Chief Scientific Officer/Director
Robert Foster
Chief Financial Officer
John Cavan
Independent Director
Thomas Adams
Independent Director
Timothy Block
Independent Director
John Brancaccio
Independent Director
Arnold Lippa
Independent Director
Peter Wijngaard
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About HEPA
Hepion Pharmaceuticals Inc., formerly ContraVir Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company. The Company is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. Its lead oral drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. CRV431 is also being developed for viral hepatitis-induced liver disease. CRV431 targets multiple biochemical pathways involved in the progression of liver disease.

Webull offers kinds of Hepion Pharmaceuticals Inc stock information, including NASDAQ:HEPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HEPA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HEPA stock methods without spending real money on the virtual paper trading platform.